Literature DB >> 3294284

Dextro-amphetamine diminishes negative symptoms in schizophrenia.

D P van Kammen1, J J Boronow.   

Abstract

Thirty schizophrenic patients received intravenous dextro-amphetamine while on and off pimozide. The results provide evidence that negative symptoms and depressed mood in schizophrenia respond in part to intravenous challenges of dextro-amphetamine. Improvement in negative symptoms while on d-amphetamine correlated significantly with subsequent improvement in the same negative symptoms while on pimozide. These results do not support the Type II model of irreversible negative symptoms in schizophrenia in our patient sample. Changes in negative symptoms may be related to state dependent changes in the dopamine system, but noradrenergic mechanisms cannot be excluded either.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3294284     DOI: 10.1097/00004850-198804000-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

Review 1.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

2.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 3.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

4.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

Review 5.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

6.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 7.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.